Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV001018604 | SCV001179860 | uncertain significance | Hereditary cancer-predisposing syndrome | 2018-02-06 | criteria provided, single submitter | clinical testing | The p.L103F variant (also known as c.309A>C), located in coding exon 2 of the BRCA2 gene, results from an A to C substitution at nucleotide position 309. The leucine at codon 103 is replaced by phenylalanine, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |